MAP2K7 and hepatocellular carcinoma: Considering our previous finding that YRDC promotes HCC cells proliferation via regulating the activity of the RAS/RAF/MEK/ERK pathway, we speculated that this pathway may involve in YRDC-mediated lenvatinib resistance.